What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Statistics
Her primary areas of study are Internal medicine, Prostate cancer, Oncology, Surgery and Cancer.
Her Internal medicine study combines topics in areas such as Gastroenterology and Endocrinology.
The Prostate-specific antigen research Susan Halabi does as part of her general Prostate cancer study is frequently linked to other disciplines of science, such as Estramustine, therefore creating a link between diverse domains of science.
Her research integrates issues of Prostate, Darolutamide, Proportional hazards model, Hazard ratio and Survival analysis in her study of Oncology.
Susan Halabi has researched Surgery in several fields, including Package insert, Guideline and Placebo.
Her research in Cancer intersects with topics in Leukemia, Vascular endothelial growth factor, Cancer research and Pathology.
Her most cited work include:
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (1635 citations)
- A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. (974 citations)
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group (925 citations)
What are the main themes of her work throughout her whole career to date?
Her scientific interests lie mostly in Internal medicine, Oncology, Prostate cancer, Cancer and Surgery.
Her work on Docetaxel, Chemotherapy, Clinical trial and Bevacizumab as part of her general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science.
Her studies in Oncology integrate themes in fields like Clinical endpoint, Proportional hazards model and Hazard ratio.
Susan Halabi interconnects Prostate, Prednisone and Urology in the investigation of issues within Prostate cancer.
Her study in Cancer is interdisciplinary in nature, drawing from both Leukemia, Gynecology, Endocrinology and Confidence interval.
Her biological study spans a wide range of topics, including Gastroenterology and Placebo.
She most often published in these fields:
- Internal medicine (67.69%)
- Oncology (56.67%)
- Prostate cancer (45.64%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (67.69%)
- Oncology (56.67%)
- Prostate cancer (45.64%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Internal medicine, Oncology, Prostate cancer, Clinical trial and Castration resistant.
Her Cancer, Cohort, Progression-free survival, Randomized controlled trial and Overall survival investigations are all subjects of Internal medicine research.
Her work on Sunitinib as part of general Oncology research is often related to In patient, thus linking different fields of science.
Her studies deal with areas such as Docetaxel, Circulating tumor cell, Androgen and Prednisone as well as Prostate cancer.
Her work in Clinical trial addresses issues such as Intensive care medicine, which are connected to fields such as Prognostic models, Guideline, Zoledronic acid and Cochrane Library.
The Castration resistant study which covers Cancer research that intersects with Hormone therapy.
Between 2017 and 2021, her most popular works were:
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 (333 citations)
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. (134 citations)
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study (122 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Statistics
Susan Halabi mostly deals with Internal medicine, Oncology, Prostate cancer, Clinical trial and In patient.
Her work in Cohort, Cancer, Progression-free survival, Docetaxel and Phases of clinical research are all subfields of Internal medicine research.
Her Cancer study combines topics in areas such as Epidemiology, Cause of death and Veterans Affairs.
Her Oncology study integrates concerns from other disciplines, such as Circulating tumor cell and Consensus conference.
Her Prostate cancer study incorporates themes from Radiation therapy, Overall survival and Prednisone.
The various areas that Susan Halabi examines in her Clinical trial study include Randomized controlled trial, Quality of life, Clinical significance, Disease and Treatment goals.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
